thalidomide has been researched along with Asthma in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study is designed to determine the effect and the potential mechanism of thalidomide in the pathogenesis of asthmatic airways using animal model of allergic asthma." | 7.81 | Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. ( Chang, YS; Cho, SH; Kang, HR; Kim, HR; Kim, HY; Kwon, HS; Lee, HS; Min, KU; Park, DE; Woo, YD, 2015) |
| "When thalidomide was administered to OVA-challenged mice, the number of eosinophils in bronchoalveolar lavage fluid (BALF) was significantly decreased." | 5.36 | Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma. ( Asano, T; Hasegawa, Y; Ito, S; Kume, H; Taki, F, 2010) |
| " The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc." | 4.90 | [Progress in PDE4 targeted therapy for inflammatory diseases]. ( Song, SD; Tang, HF, 2014) |
| "This study is designed to determine the effect and the potential mechanism of thalidomide in the pathogenesis of asthmatic airways using animal model of allergic asthma." | 3.81 | Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. ( Chang, YS; Cho, SH; Kang, HR; Kim, HR; Kim, HY; Kwon, HS; Lee, HS; Min, KU; Park, DE; Woo, YD, 2015) |
| "When thalidomide was administered to OVA-challenged mice, the number of eosinophils in bronchoalveolar lavage fluid (BALF) was significantly decreased." | 1.36 | Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma. ( Asano, T; Hasegawa, Y; Ito, S; Kume, H; Taki, F, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodimuthali, A | 1 |
| Jabaris, SS | 1 |
| Pal, M | 1 |
| Ghaderi, M | 1 |
| Oryan, S | 1 |
| Yousofvand, N | 1 |
| Eidi, A | 1 |
| Song, SD | 1 |
| Tang, HF | 1 |
| Lee, HS | 1 |
| Kwon, HS | 1 |
| Park, DE | 1 |
| Woo, YD | 1 |
| Kim, HY | 1 |
| Kim, HR | 1 |
| Cho, SH | 1 |
| Min, KU | 1 |
| Kang, HR | 1 |
| Chang, YS | 1 |
| Asano, T | 1 |
| Kume, H | 1 |
| Taki, F | 1 |
| Ito, S | 1 |
| Hasegawa, Y | 1 |
| Braddock, M | 1 |
| Murray, C | 1 |
2 reviews available for thalidomide and Asthma
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chr | 2008 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; I | 2014 |
4 other studies available for thalidomide and Asthma
| Article | Year |
|---|---|
Inhibition of Airway Contraction and Inflammation by Pomalidomide in a Male Wistar Rat Model of Ovalbumin-induced Asthma.
Topics: Airway Obstruction; Allergens; Animals; Anti-Inflammatory Agents; Asthma; Disease Models, Animal; Hu | 2019 |
Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide.
Topics: Allergens; Alum Compounds; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchi | 2015 |
Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; | 2010 |
10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Clinical Trials as Topic; Drug Delivery Systems; Drug Des | 2006 |